Lv3
220 积分 2025-01-03 加入
Oral Muvalaplin for Lowering of Lipoprotein(a)
2天前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
22天前
已完结
Structural pharmacology and mechanisms of GLP-1R signaling
28天前
已完结
Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis
1个月前
已完结
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism
1个月前
已完结
Synthesis and analgesic activity of novel L-amino acid based small molecule N-type calcium channel blockers
1个月前
已关闭
WITHDRAWN: ActRIIB small molecule inhibitor 2-67 ameliorates muscle atrophy in cancer cachexia by inhibiting the myostatin/Smad pathway
1个月前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
2个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2个月前
已关闭
Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability
2个月前
已完结
皖公网安备34019202002308
